Innoviva, Inc. INVA R2K

Healthcare · Biotechnology · United States

https://www.inva.com

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Market & Price

Market Cap

$1.58B

Current Price

$21.42

High / Low (52W)

$24.24 / $16.67

Beta

0.38

Valuation

Stock P/E

3.42

Industry PE

23.65

Forward P/E

9.69

PEG Ratio

0.32

Book Value

$18.18

Price to Book

1.18

P/S

3.76

EV/EBITDA

6.75

Dividend Yield

Profitability & Returns

ROCE

21.67%

ROE

50.72%

ROA

6.72%

Profit Margin

Op Margin

40.11%

EPS (Latest Qtr)

$2.22

EPS (TTM)

$6.26

Balance Sheet & Liquidity

Debt/Equity

0.25

Quick Ratio

19.27

Current Ratio

21.13

Debt

$331.42M

Total Assets

$1.64B

Current Assets

$727.51M

Working Capital

$677.82M

Ownership

Promoter Holding

0.99%

Chg in Prom Hold

FII / Inst Holding

107.85%

Chg in FII Hold

-0.01%

Financial Snapshot

Enterprise Value

$1.30B

Total Revenue (TTM)

$420.69M

EBITDA

$192.70M

Free Cash Flow

$105.17M

Operating Cash Flow

$183.60M

Shares Outstanding

73.81M

Gross Margin

74.10%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

7.47%

Profit 5Y

8.22%

Revenue (YoY)

10.60%

Earnings (YoY)

PROS

Strong return on equity of 50.7%.
Healthy ROCE of 21.7%.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	INVA Innoviva, Inc. R2K	21.42	3.42	$1.58B	-	21.67%	50.72%	7.47%	8.22%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	40.49M	58.56M	48.64M	69.52M	52.38M	67.09M	61.68M	79.86M	55.18M	64.11M	65.75M	75.97M	78.68M	78.95M	88.69M	85.52M	100.81M	97.86M	90.06M	108.22M	67.26M	76.37M	80.99M	67.26M	77.50M	99.90M	-	-	88.63M	100.28M	107.80M	114.61M	97.99M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.84M	10.59M	32.26M	12.67M	15.61M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	60.09M	84.99M	-	-	79.79M	89.69M	75.54M	101.94M	82.39M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	38.36M	40.94M	40.96M	62.96M	44.23M
Operating Income	5.11M	8.43M	17.29M	17.53M	25.88M	27.92M	37.66M	29.34M	47.83M	40.02M	66.41M	40.70M	62.67M	57.66M	77.22M	52.17M	59.76M	60.79M	73.64M	76.11M	75.79M	84.43M	79.48M	96.54M	94.55M	77.73M	82.55M	-	-	-	-	25.80M	54.69M	-	-	41.43M	48.75M	34.58M	38.99M	38.15M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-27.40M	83.81M	108.45M	204.98M	246.55M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.71M	4.66M	4.01M	3.31M	5.44M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-38.59M	72.60M	97.82M	195.04M	234.56M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.00M	8.91M	7.91M	30.88M	47.97M
Net Income	-	-	-	4.43M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-46.58M	63.69M	89.91M	164.15M	186.59M
Diluted EPS	-0.07	-0.04	-	0.04	0.13	0.13	0.22	0.15	0.30	0.21	0.50	0.27	0.49	0.43	2.34	0.31	0.34	0.36	0.42	0.59	0.69	0.26	0.84	0.90	0.90	0.20	0.05	2.80	0.42	0.02	0.98	0.46	-0.55	-	-	-0.74	0.77	1.08	1.94	2.22
R&D Expense	638.00K	547.00K	-	392.00K	370.00K	286.00K	-	354.00K	348.00K	311.00K	-	0	0	0	-	-	0	0	-	0	559.00K	1.01M	49.00K	38.00K	449.00K	5.84M	13.88M	11.72M	12.59M	14.99M	3.99M	3.88M	2.56M	3.55M	-	4.40M	7.98M	13.67M	-	5.24M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	133.57M	217.22M	261.00M	261.02M	336.79M	-	331.34M	310.46M	358.71M	411.33M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	13.79M	42.64M	36.60M	77.38M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	317.55M	267.82M	322.11M	333.94M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	110.55M	153.94M	155.25M	170.20M
Operating Income	-81.36M	-78.32M	-109.74M	-25.15M	-28.80M	-33.93M	31.58M	108.99M	183.60M	238.25M	246.36M	321.12M	-	207.00M	113.89M	166.87M	163.75M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	308.32M	235.04M	85.50M	369.84M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	15.79M	19.16M	22.21M	16.70M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	286.95M	194.10M	37.39M	326.86M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	66.69M	14.38M	14.00M	55.70M
Net Income	-85.30M	-83.86M	-115.34M	-18.54M	-170.70M	-168.46M	-18.76M	59.54M	134.14M	395.06M	157.29M	224.40M	-	213.92M	179.72M	23.39M	271.17M
Diluted EPS	-	-	-	-	-	-1.50	-0.16	0.53	1.17	3.53	1.43	2.02	-	2.37	2.20	0.36	3.30
R&D Expense	77.52M	75.07M	103.57M	8.15M	9.04M	7.50M	2.62M	1.39M	1.35M	0	0	1.79M	576.00K	41.43M	33.92M	13.65M	30.60M

Compounded Sales Growth

5 Years:	7.47%
1 Year:	10.60%

Compounded Profit Growth

5 Years:	8.22%
1 Year:	-

Stock Price Performance

1 Year:	+9.45%
6 Months:	-1.38%
3 Months:	-6.71%
1 Month:	-7.07%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	331.20M	258.78M	368.58M	681.25M	521.65M	408.93M	379.00M	367.34M	548.19M	724.83M	999.57M	-	1.23B	1.24B	1.30B	1.64B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	443.51M	344.22M	554.31M	727.51M
Cash & Equivalents	92.28M	47.54M	163.33M	44.78M	94.85M	143.51M	96.80M	159.18M	118.02M	73.34M	62.42M	278.10M	246.49M	-	291.05M	193.51M	304.96M	550.94M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	55.90M	40.74M	33.73M	39.17M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9.40M	14.45M	20.39M	34.97M
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	665.71M	568.55M	609.90M	462.32M
Current Liabilities	-	-	40.05M	45.50M	29.97M	84.40M	13.76M	13.49M	20.05M	34.74M	5.70M	5.37M	6.11M	-	134.97M	38.13M	236.08M	49.70M
Long Term Debt	-	-	-	-	-	-	-	733.13M	708.34M	574.36M	382.86M	377.12M	385.52M	-	444.18M	446.23M	256.32M	257.73M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	544.07M	449.08M	451.10M	269.02M
Total Equity	-134.95M	-188.99M	-22.42M	-87.05M	155.03M	299.12M	-223.35M	-342.64M	-352.99M	-242.86M	153.58M	313.50M	539.91M	-	565.79M	674.96M	691.16M	1.17B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	101.19M	95.31M	62.66M	74.64M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-127.51M	-129.60M	-130.72M	10.13M	60.98M	141.75M	223.53M	257.46M	313.11M	-	201.73M	141.06M	188.69M	196.93M
Investing Cash Flow	-	-	-	-58.28M	-219.58M	-65.06M	159.17M	-4.58M	-23.24M	3.52M	-18.00M	-314.94M	-	-56.63M	-66.76M	-63.79M	40.50M
Financing Cash Flow	-	-	-	235.87M	397.84M	149.07M	-106.92M	-97.57M	-163.19M	-237.97M	-23.78M	-29.79M	-	-55.57M	-171.84M	-13.45M	8.55M
Capital Expenditure	-744.00K	-861.00K	-3.63M	-2.59M	-2.73M	-689.00K	-7.00K	-278.00K	-0	-0	-12.00K	-13.00K	-	-67.00K	-411.00K	-4.27M	-10.50M
Free Cash Flow	-	-	-	-130.10M	-132.34M	-131.41M	10.12M	60.71M	141.75M	223.53M	257.45M	313.10M	-	201.66M	140.65M	184.42M	186.43M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	89.52M	-97.54M	111.45M	245.98M
Share Buybacks	-	-	-	-	0	0	25.64M	78.09M	97.50M	0	0	0	394.15M	8.50M	75.73M	14.78M	4.53M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	95.8%	86.3%	89.8%	81.2%
Operating Margin %	-	-	-	-	-	-	-	81.6%	84.5%	91.3%	94.4%	95.3%	-	62.5%	36.7%	46.5%	39.8%
Net Margin %	-	-	-	-	-	-	-	44.6%	61.8%	151.4%	60.3%	66.6%	-	64.6%	57.9%	6.5%	65.9%
ROE %	45.1%	374.0%	132.5%	-12.0%	-57.1%	75.4%	5.5%	-16.9%	-55.2%	257.2%	50.2%	41.6%	-	37.8%	26.6%	3.4%	23.1%
ROCE %	-	-26.9%	-51.5%	-7.4%	-4.8%	-6.7%	8.0%	30.4%	55.2%	43.9%	34.2%	32.3%	-	18.9%	9.4%	15.7%	10.3%

Shareholding Pattern

Insiders

0.99%

Institutions

107.85%

Public Float

108.93%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	15.32%	11.31M	$242.21M
2	Dimensional Fund Advisors LP	6.01%	4.44M	$95.03M
3	Vanguard Portfolio Management LLC	5.72%	4.22M	$90.50M
4	Renaissance Technologies, LLC	5.49%	4.06M	$86.87M
5	Vanguard Capital Management LLC	4.26%	3.14M	$67.29M
6	State Street Corporation	4.15%	3.06M	$65.55M
7	Millennium Management Llc	3.09%	2.28M	$48.83M
8	Sarissa Capital Management, LP	2.89%	2.13M	$45.64M
9	Systematic Financial Management, L.P.	2.74%	2.02M	$43.36M
10	Geode Capital Management, LLC	2.61%	1.93M	$41.33M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for INVA

No recent headlines available.

INVA · Healthcare

Innoviva, Inc.

About

Key Facts

Sector	Healthcare
Industry	Biotechnology
Headquarters	United States
Employees	159
Website	https://www.inva.com

Press Esc or click outside to close.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Innoviva, Inc. INVA R2K

Market & Price

Valuation

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Growth (CAGR)

PROS

CONS

Price Chart

Technical Trend

Fundamental Growth

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Explore More